Using breath analysis to identify multiple lung diseases
Exploration and Study on the Identification of Various Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath
This study is testing if analyzing breath samples can help identify different lung diseases like lung cancer and COPD in a large group of 10,000 people.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | ChromX Health Industry-sponsored |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06528418 on ClinicalTrials.gov |
What this trial studies
This observational study aims to develop an advanced algorithm that utilizes volatile organic compounds (VOCs) found in exhaled breath to diagnose various pulmonary diseases. It will recruit 10,000 participants with conditions such as lung cancer, COPD, and bronchitis, collecting breath samples for analysis using gas chromatography techniques. The study will evaluate the diagnostic accuracy of an AI model based on these breath samples, comparing results with clinical diagnostic data and imaging results.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a clear clinical diagnosis of various pulmonary diseases and the ability to provide CT imaging data.
Not a fit: Patients who are pregnant, have a history of cancers other than lung disease, or have severe organic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to earlier and more accurate diagnoses of multiple pulmonary diseases, improving patient outcomes.
How similar studies have performed: While the use of breath analysis for disease diagnosis is an emerging field, similar studies have shown promise in identifying specific conditions, making this approach both innovative and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Males or females, age must be 18 years old or above. * Patients must meet the CT imaging diagnostic criteria for different lung diseases, and patients must be able to provide electronic versions of CT image data. * Patients must have a clear clinical diagnosis. * All participants must sign a written informed consent form. Exclusion Criteria: * Pregnant women. * Individuals with a history of cancer other than lung disease. * Individuals who have undergone organ transplants or non-autologous (allogeneic) bone marrow or stem cell transplants. * Individuals with other severe organic diseases or mental illnesses. * Individuals with metabolic diseases such as diabetes, hyperlipidemia, etc. * Any other condition that researchers deem unsuitable for participation in this clinical trial.
Where this trial is running
Guangzhou, Guangdong
- The First Affiliated Hospital of Guangzhou Medical University — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Hengrui Liang, MD
- Email: hengrui_liang@163.com
- Phone: +86 15625064712
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.